EGFR mutation status in a series of Turkish non-small cell lung cancer patients.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Umit Unal, Olcun
MetadataShow full item record
CitationCalibasi-Kocal G, Amirfallah A, Sever T, Umit Unal O, Gurel D, Oztop I, Ellidokuz H, Basbinar Y. EGFR mutation status in a series of Turkish non-small cell lung cancer patients. Biomed Rep. 2020 Aug;13(2):2. doi: 10.3892/br.2020.1308. Epub 2020 Jun 2. PMID: 32509305; PMCID: PMC7271734.
AbstractEpidermal growth factor receptor (EGFR) mutations are potential markers driving carcinogenesis, and may alter the response to EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC). The frequency of EGFR mutations in patients with NSCLC differs according to sex, smoking habits and regional-based ethnicity differences. The aim of the present study was to determine the frequency of EGFR mutations in Turkish patients with NSCLC to highlight the importance of regional differences, and their associations with patient characteristics. Genomic DNA was extracted from formalin-fixed and paraffin-embedded tumor tissue sections of 409 NSCLC patients. The most common EGFR mutations in exons 18, 19, 20 and 21 were detected using BioFilmChip-based microarray assay. The overall EGFR mutation frequency was 16.6%, and the highest mutation frequencies were observed in exon 19 (6.4%) and exon 21 (7.3%). There was a higher frequency of EGFR mutations in females compared with males and in never-smokers compared with smokers (both P≤0.05). These results were similar to other European population-based studies, but not consistent Middle-Eastern based studies. The present study may contribute to understanding the gradient frequency of EGFR mutation across different ethnicities, and in designing genome wide-based collaborations that may reveal novel decision making and susceptibility mutations in EGFR in patients with NSCLC.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
RightsCopyright © 2020, Spandidos Publications.
- Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic malaysian patient population.
- Authors: Liam CK, Leow HR, How SH, Pang YK, Chua KT, Lim BK, Lai NL, Kuan YC, Pailoor J, Rajadurai P
- Issue date: 2014
- Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
- Authors: Medical Advisory Secretariat.
- Issue date: 2010
- Detection of Epidermal Growth Factor Receptor (EGFR) Gene Mutation in Formalin Fixed Paraffin Embedded Tissue by Polymerase Chain Reaction-Single Strand Conformational Polymorphism (PCR-SSCP) in Non-Small Cell Lung Cancer in the Northeastern Region of Thailand
- Authors: Saiyaros K, Kritpetcharat P, Pairojkul C, Sithithaworn J
- Issue date: 2019 May 25
- Spectrum of EGFR gene mutations in Vietnamese patients with non-small cell lung cancer.
- Authors: Vu HA, Xinh PT, Ha HT, Hanh NT, Bach ND, Thao DT, Dat NQ, Trung NS
- Issue date: 2016 Mar
- EGFR and KRAS mutations in Turkish non-small cell lung cancer patients: a pilot study.
- Authors: Bircan S, Baloglu H, Kucukodaci Z, Bircan A
- Issue date: 2014 Aug